Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Conclusions: We confirmed *a priori* identified risk factors for poor prognosis in the largest COVID-19/cancer cohort and performed initial analysis of lab parameters, informing risk assessment.

Clinical trial identification: NCT04354701.

Legal entity responsible for the study: The COVID-19 and Cancer Consortium (CCC19).

Funding: Has not received any funding.

Disclosure: P. Grivas: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (self), Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): Clovis Oncology; Honoraria (self): Driver; Honoraria (institution): EMD Serono; Honoraria (self): Exelixis; Honoraria (self): Foundation Medicine; Honoraria (self), Research grant/Funding (institution): Genentech; Honoraria (self): Genzyme; Honoraria (self): GlaxoSmithKline; Honoraria (self): Heron Therapeutics; Honoraria (self): Janssen; Honoraria (self), Research grant/Funding (institution): Merck; Honoraria (self), Research grant/Funding (institution): Mirati Therapeutics; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): Roche; Honoraria (self): Seattle Genetics; Honoraria (self), Research grant/Funding (institution): QED Therapeutics; Research grant/Funding (institution): KureIT; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Debiopharm; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Oncogenex. J. Warner: Advisory/Consultancy: IBM Watson Health; Advisory/Consultancy: Westat; Leadership role, Shareholder/Stockholder/Stock options: HemOnc.org LLC; Travel/Accommodation/Expenses: American Society of Clinical Oncology; Research grant/Funding (institution): National Cancer Institute. Y. Shyr: Advisory/Consultancy: Roche; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Johnson & Johnson; Advisory/Consultancy: GlaxoSmithKline; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Eisai. D. Shah: Research grant/Funding (institution), American Cancer Society and the Hope Foundation for Cancer Research (Mentored Research Scholar Grants in Applied and Clinical Research, MRSG-16-152-01-CCE; PI: Shah DP), and grants from the National Cancer Institute (P30 CA054174; PI: Mesa R): American Cancer Society; Research grant/Funding (institution): National Cancer Institute; Research grant/Funding (institution): Hope Foundation for Cancer Research. N.M. Kuderer: Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy: Celldex; Advisory/Consultancy: Invitae; Advisory/Consultancy: Total Health; Advisory/Consultancy: Beyond Springs; Advisory/Consultancy: Bayer; Advisory/Consultancy: Spectrum Pharmaceuticals. T.K. Choueiri: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Alexion; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Bristol-Myers Squibb/ER Squibb and sons; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Cerulean; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Eisai; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Foundation Medicine; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Exelixis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Ipsen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Tracon; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Genentech; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): F Hoffmann-La Roche/Roche/Roche Products; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): GlaxoSmithKline; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Peloton; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Prometheus Labs; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Corvus; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Calithera; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Analysis Group; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Sanofi/Aventis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Takeda; Honoraria (self): EMD Serono; Honoraria (self): Up-to-Date; Honoraria (self): NCCN Analysis Group; Honoraria (self), A healthcare communications company with several brands such as OncLive, PeerView and PER: Michael J Hennessy Associates; Honoraria (self): Research to Practice; Honoraria (self), and Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Clinical Oncology, New England Journal of Medicine, The Lancet Oncology, Heron Therapeutics: L-path. C. Painter: Shareholder/Stockholder/Stock options: Pfizer; Shareholder/Stockholder/Stock options: Epizyme; Shareholder/Stockholder/Stock options: Inovio; Shareholder/Stockholder/Stock options: OPKO Health Inc.; Shareholder/Stockholder/Stock options: Roche. M.A. Thompson: Honoraria (institution): AbbVie; Honoraria (institution): BMS; Honoraria (institution): CRAB CTC; Honoraria (institution): Denovo; Honoraria (institution): Hoosier Research Network; Honoraria (institution): Lilly; Honoraria (institution): LynxBio; Honoraria (institution): Strata Oncology; Honoraria (institution), Advisory/Consultancy: Takeda; Honoraria (institution): TG Therapeutics; Advisory/Consultancy: Adaptive; Advisory/Consultancy: AIM Specialty Health; Advisory/Consultancy: Celgene (BMS); Advisory/Consultancy: GSK; Advisory/Consultancy: VIA Oncology (now Elsevier Clinical Path); Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options: Doximity; Travel/Accommodation/Expenses: Syapse; Licensing/Royalties: UpToDate; Non-remunerated activity/ies: Strata Oncology Advisory Board. S. Peters: Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Amgen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Biocartis; Honoraria (institution), Advisory/Consultancy: Bioinvent; Honoraria (institution), Advisory/Consultancy: Blueprint Medicines; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Boehringer-Ingelheim; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Clovis; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (institution), Advisory/Consultancy: Debiopharm; Honoraria (institution), Advisory/Consultancy: Eli Lilly; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): F. Hoffmann-La Roche; Honoraria (institution), Advisory/Consultancy: Foundation Medicine; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Illumina; Honoraria (institution), Advisory/Consultancy: Janssen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck Sharp and Dohme; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Honoraria (institution), Advisory/Consultancy: Merrimack; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (institution), Advisory/Consultancy: PharmaMar; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (institution), Advisory/Consultancy: Regeneron; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Seattle Genetics; Honoraria (institution), Advisory/Consultancy: Takeda; Honoraria (institution), Advisory/Consultancy: Vaccibody; Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): Biodesix. A.R. Khaki: Shareholder/Stockholder/Stock options: Pfizer; Shareholder/Stockholder/Stock options: Merck. N.A. Pennell: Advisory/Consultancy: Astrazeneca; Advisory/Consultancy: Merck; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Genentech; Advisory/Consultancy: BMS; Advisory/Consultancy: Amgen. B. Halmos: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Research grant/Funding (institution): Boehringer-Ingelheim; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Amgen; Advisory/Consultancy: Spectrum; Advisory/Consultancy: Takeda; Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Advisory/Consultancy: Foundation One; Advisory/Consultancy, Research grant/Funding (institution): Genentech; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Advaxis; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Eli-Lilly; Research grant/Funding (institution): Mirati. G.H. Lyman: Advisory/Consultancy: G1 Therapeutics; Advisory/Consultancy: Spectrum; Advisory/Consultancy: Invitae; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Samsung; Advisory/Consultancy: Beyond Spring; Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Advisory/Consultancy: Mylan; Research grant/Funding (institution): Amgen. B.I. Rini: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck; Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (institution): AVEO; Advisory/Consultancy: Arravive; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: 3D Medicines; Advisory/Consultancy: Synthorx; Advisory/Consultancy: Surface Oncology; Shareholder/Stockholder/Stock options: PTC Therapeutics; Research grant/Funding (institution): AstraZeneca. G. Lopes: Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Blueprint Medicines; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Adaptimmune; Research grant/Funding (institution): BMS; Research grant/Funding (institution): GSK; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly; Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Travel/Accommodation/Expenses: E.R. Squibb Sons, LLC. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.2313

LBA73 The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01

P. Kvistborg[1], A. Gangaev[1], S. Ketelaars[1], S. Patiweal[1], A. Dopler[1], O. Isaeva[1], K. Hoefakker[1], S. De Biasi[2], C. Mussini[2], G. Guaraldi[2], M. Girardis[2], C. Talavera Ormeno[3], P. Hekking[3], N. Lardy[4], M. Toebes[1], R. Balderas[5], T.N. Schumacher[6], H. Ovaa[3], A. Cossarizza[2]

[1]Immunology, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; [2]Department of Medical and Surgical Sciences for Children and Adults, University of Modena, Modena, Italy; [3]Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands; [4]Department of Immunogenetics, Sanquin Diagnostics, Amsterdam, Netherlands; [5]Department of Biological Sciences, BD Bioscience, San Jose, CA, USA; [6]Immunology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, Netherlands

Background: A large global effort is ongoing to develop vaccines against SARS-CoV-2, the causative agent of COVID-19. While there is accumulating information on the antibody response against SARS-CoV-2, less is known about the SARS-CoV-2 antigens that are targeted by CD8 T cells. Such knowledge will be of high value to gain fundamental insights into the antigenic landscape of SARS-CoV-2 recognized by CD8 T cells, to develop tool allowing focused analysis of the SARS-CoV-2 specific T cell responses directly ex vivo, and to understand whether current vaccine designs are covering the CD8 T cell recognized antigens.

Methods: To address this issue, we have analyzed samples from 18 COVID-19 patients for CD8 T cell recognition of 500 predicted SARS-CoV-2-derived epitopes restricted to 10 common HLA-A and HLA-B alleles. For each HLA allele, the top 50 epitopes were selected based on predicted binding affinity and likelihood of successful proteasomal processing. To probe for CD8 T cell recognition of the selected epitope-HLA complexes, we made use of our in-house technology based on multiplexing of peptide HLA (pHLA) multimers conjugated to fluorescent dyes.

Results: In addition to previous studies showing CD8 T cell reactivity towards epitopes derived from the spike protein of SARS-CoV-2, we have identified several CD8 T cell recognized epitopes derived from the ORF1ab, including one epitope displaying clear immunodominant properties across patients positive for HLA-A*01:01. Investigation of the functional status of part of the identified responses (including 4 responses specific for the immunodominant epitope) revealed that the T cell responses were

highly dysfunctional. In addition the SARS-CoV-2 specific CD8 T cell responses displayed an increased expression of NKG2A in comparison with bulk CD8 T cells, which may explain their dysfunctional state.

Conclusions: Our data suggest that part of the ORF1ab encodes multiple CD8 T cell antigens including one immunodominant epitope. Noteworthy these epitopes were derived from a part of the viral genome that is not included in the majority of vaccine candidates in development, and this may potentially influence their clinical activity and safety profile.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.2314

LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)

D. Doroshow[1], A.L. Schmidt[2], Z. Bakouny[2], S. Bhalla[1], J.A. Steinharter[2], D. Tremblay[1], M.M. Awad[2], A.J. Kessler[1], G. Bouchard[2], M. Evans[3], F. Busser[2], B.S. Zimmerman[1], C.R. Curran[2], T. Jun[1], R. Haddad[2], Q. Qin[1], P.V. Nuzzo[2], J. Feld[1], M.D. Galsky[1], T.K. Choueiri[2]

[1]Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; [2]Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; [3]Medicine, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA

Background: The COVID-19 pandemic has rapidly altered cancer care. However, the ways in which it has done so and the associated impact at the individual and societal levels remains poorly defined.

Methods: CCOS is a multicenter prospective cohort study designed to define the impact of the pandemic on cancer care delivery and outcomes. The CCOS cohort comprised consecutive outpatients with cancer seen at two US cancer centers from March 2 to March 6, 2020 (index visit). Data was collected at baseline, retrospectively from the preceding 3 months, and prospectively at 3-month follow up. Per patient changes in numbers of visits were compared using Wilcoxon signed rank tests. Correlates of increases in telehealth visits and decreases in in-person visits were evaluated using multivariable logistic regression models. Adjusted Odds ratios [aOR] and 95% confidence intervals (CI) were reported.

Results: Of 2365 included patients, 1219 (51.6%) had a decrease in in-person visit frequency during the pandemic period relative to the preceding 3 months. Conversely, 760 (32.2%) had an increased frequency of telehealth visits (decrease in in-person and increase in telehealth visits; both $p<0.01$). 128 (5.4%) patients developed COVID-19. Compared to White patients, Black and Hispanic patients were less likely to have telehealth visits, had no significant change in frequency of in-person visits, and were more likely to develop COVID-19 (Table).

Conclusions: Significant disruptions to routine cancer care were observed during the pandemic period relative to the prior 3 months. Racial and ethnic barriers to the adoption of telehealth, and related socioeconomic factors, place these vulnerable populations simultaneously at disproportionate risk for decreased cancer-related visits and COVID infection, thereby exacerbating existing racial and ethnic health disparities.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: D. Doroshow: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Athenaeum Partners; Honoraria (self), Advisory/Consultancy: Boston Healthcare Associates. A.L. Schmidt: Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Astellas. Z. Bakouny: Non-remunerated activity/ies: Bristol Myers Squibb; Research grant/Funding (self): Genentech/ImCore. M.M. Awad: Advisory/Consultancy, Research grant/Funding (self): Bristol Myers Squibb; Advisory/Consultancy, Research grant/Funding (self): Lilly; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Genentech; Advisory/Consultancy: Merck; Advisory/Consultancy: Achilles; Advisory/Consultancy: AbbVie. R. Haddad: Advisory/Consultancy, Research grant/Funding (self): Bristol Myers Squibb; Advisory/Consultancy, Research grant/Funding (self): Merck; Advisory/Consultancy, Research grant/Funding (self): Pfizer; Advisory/Consultancy, Research grant/Funding (self): Genentech; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): GlaxoSmithKline. M.D. Galsky: Shareholder/Stockholder/Stock options: Rappta Therapeutics; Honoraria (self): BioMotiv; Honoraria (self): Janssen; Honoraria (self): Dendreon; Honoraria (self): Merck; Honoraria (self): GlaxoSmithKline; Honoraria (self): Lilly; Honoraria (self): Astellas Pharma; Honoraria (self): Genentech; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): EMD Serono; Honoraria (self): AstraZeneca; Honoraria (self): Seattle Genetics; Honoraria (self): Incyte; Honoraria (self): Alleron Therapeutics; Honoraria (self): Dracen; Honoraria (self): Inovio Pharmaceuticals; Honoraria (self): NuMab; Honoraria (self): Dragonfly Therapeutics; Honoraria (institution): Janssen Oncology; Honoraria (institution): Dendreon; Honoraria (institution): Novartis; Honoraria (institution): Bristol-Myers Squibb; Honoraria (institution): Merck; Honoraria (institution): AstraZeneca; Honoraria (institution): Genentech/Roche. T.K. Choueiri: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Alexion; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): BristolMyersSquibb; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Cerulean; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Eisai; Honoraria (self), Research grant/Funding (self): Foundation Medicine; Honoraria (self), Research grant/Funding (self): Exelixis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Ipsen; Research grant/Funding (self): 16 Tracon; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Genentech; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Roche; Honoraria (self), Research grant/Funding (self): Roche Products Limited; Honoraria (self), Research grant/Funding (self): Hoffman-LaRoche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): GlaxoSmithKline; Advisory/Consultancy, Research grant/Funding (self): Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Peloton; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Prometheus labs; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Corvus; Research grant/Funding (self): Calithera; Research grant/Funding (self): Analysis Group; Honoraria (self), Research grant/Funding (self): Sanofi/Aventis; Research grant/Funding (self): Takeda; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy: UpToDate; Honoraria (self): NCCN; Honoraria (self), Advisory/Consultancy, Dr. Choueiri reports research support from AstraZeneca, Alexion, Bayer, Bristol Myers Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, 16 Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, Takeda; Honoraria: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol Myers-Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Me: Analysis Group. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2020.08.2315

LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

J. Baena Espinar[1], V. Torri[2], J. Whisenant[3], F.R. Hirsch[4], J. Rogado[5], J. de Castro Carpeño[6], B. Halmos[7], G.L. Ceresoli[8], A. Gomez Rueda[9], M. Tiseo[10], E. Felip[11], M. Majem Tarruella[12], I. Monnet[13], U. Tapan[14], H. Wakelee[15], L-C. Huang[3], M.C. Garassino[16], S. Peters[17], L. Horn[3], M. Hellmann[18]

[1]Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; [2]Oncology Department, IRCCS "Mario Negri" Institute, Milan, Italy; [3]Hematology Oncology, Vanderbilt University of Medicine, Nashville, TN, USA; [4]Department of Medicine, Division of Medical Oncology, Mount Sinai Pediatric Associates Practice, New York, NY, USA; [5]Medical Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain; [6]Department of Oncology, Hospital Universitario La Paz, Madrid, Spain; [7]Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA; [8]Medical Oncology, Medical Oncology, Cliniche Humanitas Gavazzeni Bergamo, Italy, Bergamo, Italy; [9]Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; [10]Medical Oncology Department, University Hospital of Parma, Parma, Italy; [11]Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; [12]Area General de Assaigns Clinics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; [13]Pneumologie, CH Intercommunal de Créteil, Créteil, France; [14]Dept. of General Internal Medicine Hematology & Medical Oncology, Boston Medical Center, Boston, MA, USA; [15]Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA; [16]Medical Thoracic Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy; [17]Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne,

Table: LBA74

N (%); aOR (95% CI)*

	Increase in telehealth visits	Decrease in in-person visits	COVID-19 diagnosis
Non-Hispanic White	508 (37.8%) 1.00 (control)	716 (53.3%) 1.00 (control)	47 (3.5%) 1.00 (control)
Non-Hispanic Black	69 (23.8%) **0.69 (0.50 − 0.94)**	151 (50.5%) 0.93 (0.70 − 1.23)	27 (9.0%) **1.86 (1.10 − 3.11)**
Hispanic	65 (21.9%) **0.71 (0.51 − 0.98)**	154 (51.9%) 1.10 (0.83 − 1.46)	41 (13.8%) **3.19 (2.00 − 5.10)**
Other	43 (25.9%) 0.90 (0.60 − 1.32)	82 (49.4%) 0.93 (0.65 − 1.32)	2 (1.2%) **0.25 (0.04 − 0.84)**

* Adjusted for cancer disease group, cancer center, cancer status, and receipt of systemic therapy (during index week).